Sinemet (comparator) — Competitive Intelligence Brief

Sinemet (comparator) (Sinemet (comparator)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine precursor with peripheral decarboxylase inhibitor. Area: Neurology.

marketed Dopamine precursor with peripheral decarboxylase inhibitor Aromatic L-amino acid decarboxylase (AADC); dopaminergic system Neurology Small molecule

Target snapshot

Sinemet (comparator) (Sinemet (comparator)) — XenoPort, Inc.. Sinemet combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor) to increase dopamine levels in the brain while preventing peripheral conversion of levodopa.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sinemet (comparator) TARGET	Sinemet (comparator)	XenoPort, Inc.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic L-amino acid decarboxylase (AADC); dopaminergic system
L-DOPA/DDCI	L-DOPA/DDCI	Bial - Portela C S.A.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopaminergic system
controlled-release levodopa / carbidopa	controlled-release levodopa / carbidopa	Pfizer	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopamine pathway
Levodopa and carbidopa	Levodopa and carbidopa	NeuroDerm Ltd.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (inhibited by carbidopa)
Levodopa Benserazide Madopar	Levodopa Benserazide Madopar	IRCCS San Raffaele Roma	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic amino acid decarboxylase (inhibited by benserazide)
levodopa/dopa decarboxylase inhibitor	levodopa/dopa decarboxylase inhibitor	Bial - Portela C S.A.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (peripheral inhibition); dopamine receptors (central effect)
Levodopa + benserazide	Levodopa + benserazide	University of Buenos Aires	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (peripheral inhibition)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine precursor with peripheral decarboxylase inhibitor class)

1. Bial - Portela C S.A. · 2 drugs in this class
2. IRCCS San Raffaele Roma · 2 drugs in this class
3. NeuroDerm Ltd. · 1 drug in this class
4. Pfizer · 1 drug in this class
5. Ross D. Zafonte, MD · 1 drug in this class
6. University of Buenos Aires · 1 drug in this class
7. AbbVie · 1 drug in this class
8. XenoPort, Inc. · 1 drug in this class
9. Intec Pharma Ltd. · 1 drug in this class